Core Viewpoint - The report highlights the performance and investment strategy of the Great Wall Healthcare Mixed Securities Investment Fund for the second quarter of 2025, emphasizing its focus on the healthcare industry and the fund's net value growth during the period [1][10]. Fund Overview - Fund Name: Great Wall Healthcare Mixed Fund - Fund Code: 000339 - Fund Type: Contractual open-end fund - Total Fund Shares at Period End: 117,458,484.44 shares - Investment Objective: Focus on listed companies in the healthcare industry, aiming for performance that exceeds the benchmark while controlling risks [1][2]. Investment Strategy - The fund employs a mixed investment strategy, adjusting asset allocation based on market conditions. It combines top-down and bottom-up approaches to analyze macroeconomic factors and the fundamentals of investable stocks [2][3]. - The healthcare sector includes various sub-industries such as pharmaceuticals, traditional Chinese medicine, biological products, medical services, and medical devices. The fund selects outstanding companies from these sub-industries for its stock portfolio [2][3]. Performance Benchmark - The performance benchmark is composed of 90% of the CSI Pharmaceutical and Health Index return and 10% of the China Bond Composite Wealth Index return [3]. Risk and Return Characteristics - The fund is characterized by a long-term average risk and expected return that is lower than equity funds but higher than bond and money market funds, categorizing it as a high-risk, high-return product [3]. Financial Performance - The net value growth rate of the Great Wall Healthcare Mixed Fund A for the past three months was 17.49%, while the benchmark return was 1.41% [10]. - Over the past six months, the fund's growth rate was 2.23%, compared to a benchmark return of 32.19% [10]. - The fund's performance over the past year showed a net value growth rate of 35.19%, with a benchmark return of 10.13% [10]. Investment Composition - As of the report period, the fund's total assets included approximately 265,126,026.09 yuan in stocks, accounting for 71.42% of the total fund assets [11]. - The fund's investment strategy mandates that at least 80% of its non-cash assets be invested in stocks of listed companies in the healthcare sector [6]. Fund Management - The fund manager, Great Wall Fund Management Co., Ltd., has adhered to relevant laws and regulations, ensuring the fair treatment of different investors and maintaining a disciplined investment approach [7][9].

Core Viewpoint - The article discusses the performance forecasts of listed companies for the first half of the year, highlighting the trends in net profit changes and the overall market sentiment towards these companies [1][2]. Group 1: Company Performance Forecasts - As of June 16, a total of 8 companies have announced their performance forecasts for the first half of the year, with 4 companies expecting to maintain profits, 3 expecting slight increases, and 1 expecting a slight decrease [2]. - Lixun Precision, a leader in the "fruit chain" sector, anticipates a net profit of approximately 6.475 billion to 6.745 billion yuan, representing a growth of 20% to 25% compared to the previous year [4]. - Ying Shi Innovation, Haiyang Technology, and Guqi Woolen Materials are also expected to see net profit increases exceeding 10% [5]. Group 2: Detailed Company Insights - Ying Shi Innovation forecasts a revenue of 3.214 billion to 3.815 billion yuan, with a year-on-year growth of 32.38% to 57.10%, and a net profit of 494 million to 583 million yuan, reflecting a change of -4.65% to 12.49% [5]. - Haiyang Technology expects a revenue decline of 10.66% to 14.30% and a net profit change of -2.05% to 10.83% [6]. - Guqi Woolen Materials anticipates a revenue of 520 million to 580 million yuan, with a year-on-year change of 1.71% to 13.44%, and a net profit of 98 million to 107 million yuan, reflecting a change of 1.42% to 10.73% [6]. Group 3: Market Trends and Insights - The article notes that companies with strong performance in the first half are likely to attract more investment, especially those with high growth and favorable industry conditions [6]. - The report highlights five characteristics of stocks that performed well during the mid-year reporting season, including strong industry performance, significant growth above industry averages, low or mid-level valuations, clear growth catalysts for the second half, and high dividend payouts [7]. - The Chinese medicine industry is expected to show improved revenue and profit growth in the second quarter of 2025, with a stable cash flow and low volatility in profit growth [7].